JP2019503172A - 定常領域の変異を有する二重特異性抗体およびその使用 - Google Patents

定常領域の変異を有する二重特異性抗体およびその使用 Download PDF

Info

Publication number
JP2019503172A
JP2019503172A JP2018533745A JP2018533745A JP2019503172A JP 2019503172 A JP2019503172 A JP 2019503172A JP 2018533745 A JP2018533745 A JP 2018533745A JP 2018533745 A JP2018533745 A JP 2018533745A JP 2019503172 A JP2019503172 A JP 2019503172A
Authority
JP
Japan
Prior art keywords
domain
amino acid
residues
acid substitution
bispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018533745A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019503172A5 (enExample
Inventor
サシセカラン，　ラム
ラム サシセカラン，
カナン サラカラマン，
カナン サラカラマン，
ビジャ スブラマニアン，
ビジャ スブラマニアン，
エドゥアルド フライシャー，
エドゥアルド フライシャー，
アンドリュー ピーター ハタス，
アンドリュー ピーター ハタス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2019503172A publication Critical patent/JP2019503172A/ja
Publication of JP2019503172A5 publication Critical patent/JP2019503172A5/ja
Priority to JP2021087487A priority Critical patent/JP2021119793A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2018533745A 2015-12-28 2016-12-28 定常領域の変異を有する二重特異性抗体およびその使用 Pending JP2019503172A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021087487A JP2021119793A (ja) 2015-12-28 2021-05-25 定常領域の変異を有する二重特異性抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562271844P 2015-12-28 2015-12-28
US62/271,844 2015-12-28
PCT/US2016/068808 WO2017117179A1 (en) 2015-12-28 2016-12-28 Bispecific antibodies having constant region mutations and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021087487A Division JP2021119793A (ja) 2015-12-28 2021-05-25 定常領域の変異を有する二重特異性抗体およびその使用

Publications (2)

Publication Number Publication Date
JP2019503172A true JP2019503172A (ja) 2019-02-07
JP2019503172A5 JP2019503172A5 (enExample) 2020-02-13

Family

ID=57822093

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018533745A Pending JP2019503172A (ja) 2015-12-28 2016-12-28 定常領域の変異を有する二重特異性抗体およびその使用
JP2021087487A Pending JP2021119793A (ja) 2015-12-28 2021-05-25 定常領域の変異を有する二重特異性抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021087487A Pending JP2021119793A (ja) 2015-12-28 2021-05-25 定常領域の変異を有する二重特異性抗体およびその使用

Country Status (7)

Country Link
US (1) US11459405B2 (enExample)
EP (1) EP3397646A1 (enExample)
JP (2) JP2019503172A (enExample)
CN (1) CN108779182A (enExample)
AU (1) AU2016381605A1 (enExample)
CA (1) CA3010027A1 (enExample)
WO (1) WO2017117179A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023513900A (ja) * 2020-02-12 2023-04-04 イーライ リリー アンド カンパニー 抗体または抗原結合フラグメントの結晶化

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10077298B2 (en) 2012-11-28 2018-09-18 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
FI3359576T3 (fi) 2015-10-08 2025-01-29 Zymeworks Bc Inc Antigeeniä sitovia polypeptidirakenteita, jotka käsittävät kappa- ja lamba-kevytketjuja, ja niiden käyttötapoja
WO2018059502A1 (en) 2016-09-29 2018-04-05 Beijing Hanmi Pharmaceutical Co., Ltd. Heterodimeric immunoglobulin constructs and preparation methods thereof
CA3043652A1 (en) 2016-11-18 2018-05-24 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
US20190389972A1 (en) * 2018-01-15 2019-12-26 I-Mab Modified ck and ch1 domains
WO2019153200A1 (zh) * 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
JP2021512624A (ja) * 2018-02-11 2021-05-20 ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 抗ｐｄ−１／抗ｖｅｇｆ天然抗体構造様ヘテロ二量体型二重特異性抗体及びその製造
MX2020011552A (es) 2018-05-03 2020-11-24 Genmab Bv Combinaciones de variantes de anticuerpos y usos de las mismas.
CN109053895B (zh) * 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
US20220023342A1 (en) * 2018-11-30 2022-01-27 Institut Gustave Roussy Anti-neuropilin-1 and anti-programmed cell death-1 combination therapy for treating cancer
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
CN110272495A (zh) * 2019-06-11 2019-09-24 南京华岩生物技术有限公司 一种能结合两种抗原的双特异性结合的免疫球蛋白及其用途
CN114450297A (zh) * 2019-07-12 2022-05-06 普罗维瓦疗法香港有限公司 Il-2组合物及其使用方法
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011508604A (ja) * 2008-01-07 2011-03-17 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
WO2013065708A1 (ja) * 2011-10-31 2013-05-10 中外製薬株式会社 重鎖と軽鎖の会合が制御された抗原結合分子
WO2014082179A1 (en) * 2012-11-28 2014-06-05 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
WO2014124326A1 (en) * 2013-02-08 2014-08-14 Stem Centrx, Inc. Novel multispecific constructs
JP2014522644A (ja) * 2011-07-07 2014-09-08 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク 多重特異性抗体
WO2015150447A1 (en) * 2014-04-02 2015-10-08 F. Hoffmann-La Roche Ag Multispecific antibodies
WO2015173756A2 (en) * 2014-05-16 2015-11-19 Pfizer Inc. Bispecific antibodies
WO2015181805A1 (en) * 2014-05-28 2015-12-03 Zymeworks Inc. Modified antigen binding polypeptide constructs and uses thereof
JP2015536349A (ja) * 2012-11-21 2015-12-21 アムジエン・インコーポレーテツド ヘテロ二量体免疫グロブリン

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009131239A1 (ja) * 2008-04-25 2009-10-29 Kyowa Hakko Kirin Co Ltd 安定な多価抗体
SG10201602371VA (en) 2011-03-25 2016-04-28 Glenmark Pharmaceuticals Sa Hetero-dimeric immunoglobulins
MX382731B (es) * 2013-09-27 2025-03-13 Chugai Pharmaceutical Co Ltd Metodo para producir heteromultimeros de polipeptidos.
JP7710827B2 (ja) * 2017-06-05 2025-07-22 ヤンセン バイオテツク，インコーポレーテツド 非対称なｃｈ２－ｃｈ３領域の変異を有する、操作された多重特異性抗体及び他の多量体タンパク質

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011508604A (ja) * 2008-01-07 2011-03-17 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
JP2014522644A (ja) * 2011-07-07 2014-09-08 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク 多重特異性抗体
WO2013065708A1 (ja) * 2011-10-31 2013-05-10 中外製薬株式会社 重鎖と軽鎖の会合が制御された抗原結合分子
JP2015536349A (ja) * 2012-11-21 2015-12-21 アムジエン・インコーポレーテツド ヘテロ二量体免疫グロブリン
WO2014082179A1 (en) * 2012-11-28 2014-06-05 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
WO2014124326A1 (en) * 2013-02-08 2014-08-14 Stem Centrx, Inc. Novel multispecific constructs
WO2015150447A1 (en) * 2014-04-02 2015-10-08 F. Hoffmann-La Roche Ag Multispecific antibodies
WO2015173756A2 (en) * 2014-05-16 2015-11-19 Pfizer Inc. Bispecific antibodies
WO2015181805A1 (en) * 2014-05-28 2015-12-03 Zymeworks Inc. Modified antigen binding polypeptide constructs and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KLEIN CHRISTIAN: "PROGRESS IN OVERCOMING THE CHAIN ASSOCIATION ISSUE IN BISPECIFIC HETERODIMERIC IGG ANTIBODIES", MABS, vol. VOL:4, NR:6, JPN5019002085, November 2012 (2012-11-01), US, pages 653 - 663, ISSN: 0004423088 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 25, JPN6021000249, 18 June 2010 (2010-06-18), pages 19637 - 19646, ISSN: 0004423089 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023513900A (ja) * 2020-02-12 2023-04-04 イーライ リリー アンド カンパニー 抗体または抗原結合フラグメントの結晶化
JP7399305B2 (ja) 2020-02-12 2023-12-15 イーライ リリー アンド カンパニー 抗体または抗原結合フラグメントの結晶化

Also Published As

Publication number Publication date
US20190023810A1 (en) 2019-01-24
EP3397646A1 (en) 2018-11-07
JP2021119793A (ja) 2021-08-19
CA3010027A1 (en) 2017-07-06
WO2017117179A8 (en) 2018-07-12
CN108779182A (zh) 2018-11-09
US11459405B2 (en) 2022-10-04
AU2016381605A1 (en) 2018-07-12
WO2017117179A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
US11912773B2 (en) Fc variants and methods for their production
JP6161540B2 (ja) Ｆｃ変異体及びそれらの生産方法
RU2624027C2 (ru) Получение гетеромультимерных белков
JP2021119793A (ja) 定常領域の変異を有する二重特異性抗体およびその使用
RU2573915C2 (ru) Содержащие суперспираль и/или привязку белковые комплексы и их применение
JP2019503172A5 (enExample)
JP7253518B2 (ja) 哺乳動物細胞を用いたヘテロ多量体タンパク質の生成

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210525

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211008